Literature DB >> 19023279

Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients.

Robert S Rosenson1.   

Abstract

Adiponectin is an adipose-secreted hormone with anti-inflammatory properties mediated by inhibition of nuclear factor-kappaB (NF-kappaB) signaling. This study investigates whether fenofibrate alters adiponectin levels in patients with hypertriglyceridemia and the metabolic syndrome, and examines the association of adiponectin with circulating inflammatory markers and whole blood cytokine production. The effects of fenofibrate (160 mg/day) on adiponectin and other inflammatory markers were investigated in a 12-week randomized, placebo-controlled trial in 55 patients with hypertriglyceridemia (plasma triglycerides > or =1.7 mmol/l and <6.8 mmol/l), central obesity and other characteristics of the metabolic syndrome who were not receiving lipid-altering therapies. In the fenofibrate group, adiponectin levels increased from 4.10 to 4.50 microg/ml (+7.7%); in the placebo group, adiponectin levels increased by 1.8%; (P = 0.0005). In multivariate models including age, gender, and waist circumference, there were inverse correlations between changes in adiponectin and vascular cell adhesion molecule-1 (VCAM-1) (r = -0.54, P < 0.0001) and intercellular adhesion molecule-1 (ICAM-1) (r = -0.57, P < 0.0001), and C-reactive protein (CRP) (r = -0.40, P = 0.0041); lipopolysaccharide (LPS)-stimulated production of tumor necrosis factor-alpha (TNF-alpha) (r = -0.30, P = 0.035), interleukin (IL)-1beta (r = -0.44, P = 0.0016), monocyte chemotactic protein-1 (MCP-1) (r = -0.46, P = 0.001), and macrophage inflammatory protein-1alpha (MIP-1alpha) (r = -0.45, P = 0.0012). Fenofibrate (160 mg/day) raised adiponectin levels in patients with hypertriglyceridemia and the metabolic syndrome. Changes in adiponectin were significantly and inversely associated with changes in multiple inflammatory markers. These data suggest that adiponectin may contribute to the anti-inflammatory effects of fenofibrate.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19023279     DOI: 10.1038/oby.2008.530

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  24 in total

Review 1.  Fenofibrate: a review of its use in dyslipidaemia.

Authors:  Kate McKeage; Gillian M Keating
Journal:  Drugs       Date:  2011-10-01       Impact factor: 9.546

2.  Effect of fish and krill oil supplementation on glucose tolerance in rabbits with experimentally induced obesity.

Authors:  Zhenya Ivanova; Bodil Bjørndal; Natalia Grigorova; Anton Roussenov; Ekaterina Vachkova; Kjetil Berge; Lena Burri; Rolf Berge; Spaska Stanilova; Anelia Milanova; Georgi Penchev; Rita Vik; Vladimir Petrov; Teodora Mircheva Georgieva; Boycho Bivolraski; Ivan Penchev Georgiev
Journal:  Eur J Nutr       Date:  2014-10-15       Impact factor: 5.614

Review 3.  Review: adiponectin in retinopathy.

Authors:  Zhongjie Fu; Yan Gong; Chatarina Löfqvist; Ann Hellström; Lois E H Smith
Journal:  Biochim Biophys Acta       Date:  2016-05-04

4.  Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate.

Authors:  Alexis C Frazier-Wood; Stella Aslibekyan; Ingrid B Borecki; Paul N Hopkins; Chao-Qiang Lai; Jose M Ordovas; Robert J Straka; Hemant K Tiwari; Donna K Arnett
Journal:  Pharmacogenet Genomics       Date:  2012-10       Impact factor: 2.089

Review 5.  Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease.

Authors:  Michael S Kostapanos; Anastazia Kei; Moses S Elisaf
Journal:  World J Hepatol       Date:  2013-09-27

Review 6.  Adiponectin and cardiovascular health: an update.

Authors:  Xiaoyan Hui; Karen S L Lam; Paul M Vanhoutte; Aimin Xu
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

7.  Pharmacological effects of lipid-lowering drugs on circulating adipokines.

Authors:  Desiree Wanders; Eric P Plaisance; Robert L Judd
Journal:  World J Diabetes       Date:  2010-09-15

8.  Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms.

Authors:  Deepa S De Silva; Richard M Wilson; Christoph Hutchinson; Peter C Ip; Anthony G Garcia; Steve Lancel; Masa Ito; David R Pimentel; Flora Sam
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-04-24       Impact factor: 4.733

9.  Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.

Authors:  Renata Belfort; Rachele Berria; John Cornell; Kenneth Cusi
Journal:  J Clin Endocrinol Metab       Date:  2010-01-08       Impact factor: 5.958

10.  PPARα Agonist Fenofibrate Ameliorates Learning and Memory Deficits in Rats Following Global Cerebral Ischemia.

Authors:  Ai-Guo Xuan; Yan Chen; Da-Hong Long; Meng Zhang; Wei-Dong Ji; Wen-Juan Zhang; Ji-Hong Liu; Le-Peng Hong; Xiao-Song He; Wen-Liang Chen
Journal:  Mol Neurobiol       Date:  2014-09-23       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.